February 12, 2015 / 7:22 AM / 3 years ago

BRIEF-Thrombogenics says Jetrea drug gains approval in Argentina, Israel

Feb 12 (Reuters) - Thrombogenics NV :

* Announces that Jetrea (Ocriplasmin) has gained approval in Argentina and Israel

* Thrombogenics' partner Alcon, which is commercializing Jetrea outside the US, will be responsible for the launch of the drug in Argentina and Israel.

* Jetrea has been indicated for the treatment of adults with vitreomacular traction (VMT) Source text: (bit.ly/1ApXAOF) Further company coverage: (Bengaluru Newsroom; +44 207 542 1810)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below